Deep Track Capital, LP and Related Entities File Schedule 13G for Akero Therapeutics, Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 4,400,000 shares of Akero Therapeutics, Inc. common stock, representing 5.50% of the outstanding shares. The filing indicates that the shares are held for investment purposes and not for influencing control of the issuer. The reporting entities include Deep Track Capital, LP (an investment adviser), Deep Track Biotechnology Master Fund, Ltd. (a Cayman Islands company), and David Kroin (a managing member and director). The filing is made pursuant to Rule 13d-1(c) and includes a joint filing statement acknowledging shared responsibility for the accuracy and completeness of the information provided.